Market Movers

Texas Pacific Land Corporation (TPL)

1114.46 USD -89.20 (-7.41%) Volume: 0.16M

Texas Pacific Land Corporation’s stock price currently stands at 1114.46 USD, experiencing a dip of -7.41% this trading session, despite its impressive YTD performance showing a surge of +124.13%, with a trading volume of 0.16M.

Latest developments on Texas Pacific Land Corporation

Today, Texas Pacific Land Corp’s stock price experienced fluctuations following key events in the market. Horizon Kinetics asset management made significant investments in the company, purchasing $1,231 and $1,180 worth of Texas Pacific Land Corp shares. Additionally, Virtu Financial LLC reduced its holdings in the company. These movements come amidst the backdrop of the stock’s impressive performance over the past decade, with $100 invested in Texas Pacific Land Corp 10 years ago now worth a substantial amount. Investors are closely monitoring these developments to gauge the impact on the company’s stock price.

Texas Pacific Land Corporation on Smartkarma

Analyst Hamed Khorsand from Smartkarma recently published a research report on Texas Pacific Land, titled “TPL: Oily Water of Gold”. Khorsand has a bullish outlook on the company, highlighting the growth potential in TPL’s water sales beyond its land acreage. Despite a decline in oil and gas royalties, TPL’s water business continues to shine, providing added value to the company. Khorsand believes that TPL’s revenue diversification away from oil and gas could attract more investor attention, potentially leading to a higher stock valuation.

A look at Texas Pacific Land Corporation Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, Texas Pacific Land Corporation has a mixed outlook for the long term. While the company scores moderately on factors such as Value, Dividend, and Growth, it excels in Resilience and Momentum, with a score of 5 for both. This indicates that Texas Pacific Land Corporation is well-positioned to weather economic uncertainties and has strong positive momentum in its operations.

As the owner of valuable land tracts in Texas, previously owned by the Texas and Pacific Railway Co., Texas Pacific Land Corporation generates income from various sources including land sales, oil and gas royalties, grazing leases, and interest. With a focus on resilience and momentum, the company may continue to see steady growth and stability in the long term, despite scoring average on value, dividend, and growth factors.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma

CrowdStrike Holdings, Inc. (CRWD)

349.18 USD -27.24 (-7.24%) Volume: 4.73M

CrowdStrike Holdings, Inc.’s stock price currently stands at 349.18 USD, experiencing a dip of -7.24% this trading session, with a trading volume of 4.73M. Despite the recent decline, CRWD has seen a substantial increase of +39.21% YTD, showcasing resilience and potential for growth in the cybersecurity market.

Latest developments on CrowdStrike Holdings, Inc.

Crowdstrike Holdings, Inc. (NASDAQ:CRWD) has seen a surge in its stock price recently, with analysts adjusting their price targets based on market conditions. The company’s high visibility and longer-term growth acceleration have attracted investor attention, leading to a 9.8% return this week and a five-year gain of 711% for shareholders. CrowdStrike also achieved a significant milestone, hitting $1 billion in sales with their partnership with SHI International. Additionally, the company’s executive sold $1.66 million in shares as the stock nears a 52-week high. With new partnerships and positive reports, CrowdStrike continues to be a cybersecurity leader in the industry.

CrowdStrike Holdings, Inc. on Smartkarma

Analysts on Smartkarma are closely following Crowdstrike Holdings, a cybersecurity company, with mixed sentiments. Baptista Research‘s report highlights the company’s strengths in achieving key milestones like surpassing $4 billion in annual recurring revenue. However, they also point out challenges, such as a recent global IT outage that has raised concerns about the company’s resilience and platform reliability.

On the other hand, Jesus Rodriguez Aguilar’s analysis focuses on Crowdstrike’s positive financial results, leading to its inclusion in the S&P 500 index. This move was anticipated by investors, driven by improved profitability and operational efficiency. The report mentions that Crowdstrike’s inclusion in the index will impact liquidity and increase the representation of cybersecurity stocks, with a median consensus price target of $400 for the company.

A look at CrowdStrike Holdings, Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, Crowdstrike Holdings has a positive long-term outlook. With high scores in Growth, Resilience, and Momentum, the company is positioned for strong performance in the future. The company’s focus on cybersecurity products and services to prevent breaches, along with its global customer base, indicates a promising trajectory ahead.

Although Crowdstrike Holdings scored lower in Value and Dividend, the high scores in Growth, Resilience, and Momentum outweigh these factors. The company’s innovative approach to cybersecurity, coupled with its strong customer base and leading threat intelligence, positions it well for continued success in the long term. Investors may find Crowdstrike Holdings to be a promising investment opportunity based on its overall Smartkarma Smart Scores.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma

Align Technology, Inc. (ALGN)

212.69 USD -16.12 (-7.05%) Volume: 0.96M

Align Technology, Inc.’s stock price stands at 212.69 USD, experiencing a dip of 7.05% this trading session with a trading volume of 0.96M, and a year-to-date percentage change of -18.89%, highlighting a significant downward trend in ALGN’s market performance.

Latest developments on Align Technology, Inc.

Align Technology, Inc. stock has been underperforming the Nasdaq recently, with a decrease in share price on Monday despite advances in orthodontic education for doctors treating growing patients. The National Bank of Canada also increased its stake in Align Technology by 25.7% in the third quarter. This comes amidst a larger trend in the dental equipment market, with a projected CAGR of 4.9% by 2031, featuring companies such as Planmeca Group and Align Technology Inc.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma

Humana Inc. (HUM)

239.85 USD +5.96 (+2.55%) Volume: 2.66M

Humana Inc.’s stock price experienced a positive surge of +2.55% this trading session, currently standing at 239.85 USD per share. Despite a high trading volume of 2.66M, the healthcare company’s stock has seen a significant decrease of -47.61% YTD, reflecting volatility in its market performance.

Latest developments on Humana Inc.

Humana Inc (NYSE:HUM) stock price experienced fluctuations today amidst various factors influencing the market. Following an analyst upgrade, Humana’s shares traded up 3.1%, providing a positive outlook for investors. However, the overall health care sector faced challenges as President Trump’s latest promise regarding ‘middlemen’ caused Cigna and Humana’s stocks to plunge. Despite the leadership transition and star ratings challenge highlighted in Humana’s SWOT analysis, the company’s shares reaffirmed a neutral rating due to earnings risks. As a result, Humana’s stock price closed down 6.1%, presenting both potential buying opportunities and uncertainties for investors.

Humana Inc. on Smartkarma

According to a recent report by Baptista Research on Smartkarma, Humana Inc, a major player in the U.S. health insurance market, is being considered as a potential acquisition target by its rival, Cigna. The report highlights that informal talks between Cigna and Humana have resumed, indicating a possible acquisition deal in the works. This news comes at a time when Humana is facing challenges due to changes in the government’s Medicare plan ratings, affecting its performance.

The research report by Baptista Research leans towards a bullish sentiment on Humana Inc, suggesting that the company could be a lucrative target for acquisition by Cigna. The report titled “Humana The Next Major Acquisition Target for Cigna? The Surprising Reasons It Might Go Through!” delves into the potential reasons behind this move and the implications it could have on the U.S. health insurance market. Analysts at Baptista Research provide valuable insights into the dynamics of this potential acquisition, shedding light on the strategic considerations at play for both companies.

A look at Humana Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, Humana Inc. shows a positive long-term outlook. With high scores in Value and Dividend, the company is seen as a solid investment option. Its strong focus on providing coordinated health care services through various plans and products contributes to its resilience in the market. Although the Growth and Momentum scores are slightly lower, Humana Inc.’s overall outlook remains promising, making it a favorable choice for investors looking for stability and potential growth.

Humana Inc. is a managed health care company operating in the United States and Puerto Rico. Offering a range of health care services through different organizations and plans, the company caters to employer groups, government-sponsored plans, and individuals. With its emphasis on value and dividends, Humana Inc. demonstrates its commitment to providing quality care while also delivering returns to its shareholders. Despite facing some challenges in growth and momentum, the company’s strong foundation and market presence position it well for the future.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma

Molina Healthcare, Inc. (MOH)

296.59 USD +4.81 (+1.65%) Volume: 0.88M

With a robust trading session, Molina Healthcare, Inc.’s stock price stands at 296.59 USD, marking a noteworthy +1.65% rise, backed by a solid trading volume of 0.88M. Despite a YTD percentage change of -18.22%, the healthcare giant continues to be a focal point in the stock market.

Latest developments on Molina Healthcare, Inc.

Molina Healthcare has been making significant moves in the healthcare industry recently, with the company securing major contracts to serve dual eligible populations in Michigan and Idaho through 2026. This expansion of services has caught the attention of analysts, with JPMorgan seeing Molina Healthcare stock as fairly valued entering 2025. Despite receiving a neutral rating from JPMorgan Chase & Co., experts remain optimistic about the company’s strong fundamentals. In addition, Molina Healthcare is set to host a seasonal depression awareness event in Laredo, showcasing their commitment to community health initiatives. These developments have contributed to the excitement surrounding Molina Healthcare‘s stock price movements today.

Molina Healthcare, Inc. on Smartkarma

Analysts on Smartkarma, such as Baptista Research, have been covering Molina Healthcare closely. In a recent report titled “Molina Healthcare Inc.: These Are The 6 Biggest Factors Impacting Its Performance In 2025 & Beyond! – Major Drivers,” Baptista Research highlighted the company’s mixed performance in the third quarter of 2024. Despite facing challenges such as upward pressure on medical costs, Molina Healthcare reported adjusted earnings per share of $6.01 on $9.7 billion of premium revenue. The company maintained a robust adjusted pre-tax margin of 4.5%, showcasing a balanced business portfolio.

A look at Molina Healthcare, Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, Molina Healthcare has a positive long-term outlook. With high scores in Growth and Resilience, the company is poised for continued expansion and stability in the future. This indicates that Molina Healthcare is well-positioned to grow its business and navigate challenges effectively.

Despite a lower score in Dividend, Molina Healthcare‘s overall outlook remains strong. The company’s focus on providing healthcare services to low-income families and individuals, combined with its presence in multiple states, showcases its commitment to serving its community. With a solid foundation in place, Molina Healthcare is likely to maintain its momentum and drive success in the managed care industry.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma

LKQ Corporation (LKQ)

36.99 USD +0.38 (+1.04%) Volume: 3.66M

Explore LKQ Corporation’s stock price performance, trading at 36.99 USD, witnessing an upswing this session by +1.04%, backed by a trading volume of 3.66M. Despite the positive momentum, the stock has observed a YTD decrease of -22.14%, reflecting its volatile journey in the market.

Latest developments on LKQ Corporation

LKQ Corp, a top pick in the automotive aftermarket sector according to Jefferies, saw its stock price fall on Tuesday, underperforming the market. Despite this, LKQ’s stock price managed to rise by 1.1%. However, concerns have been raised about the company’s declining stock performance despite decent financials. Retirement Systems of Alabama recently sold shares in LKQ Co., further impacting the stock price. This follows a previous fall in stock price on Monday, where LKQ underperformed the market once again, with a 0.1% decrease. Despite these fluctuations, LKQ’s stock price managed to trade 0.5% higher, reflecting the ongoing volatility in the market.

LKQ Corporation on Smartkarma

Analysts at Baptista Research have been closely monitoring Lkq Corp on Smartkarma, providing insightful coverage on the company’s performance and future outlook. In their research reports, such as “LKQ Corporation: What Is The Expected Impact Of Revenue Diversification & Margin Improvement Strategies? – Major Drivers,” they delve into the challenges and strategic maneuvers impacting Lkq Corp‘s market position. With a bullish sentiment, Baptista Research evaluates factors influencing the company’s price and conducts independent valuations using a Discounted Cash Flow methodology.

Furthermore, Baptista Research‘s analysis on Lkq Corp‘s focus on niche markets with high margin potential and adoption of digital and technological solutions, as seen in reports like “LKQ Corporation: Adoption and Expansion of Digital and Technological Solutions! – Major Drivers,” highlights the complexities and opportunities facing the company. Despite economic pressures and operational headwinds, Lkq Corp‘s strategic growth initiatives and commitment to operational excellence set a clear path for future developments, as outlined by Baptista Research‘s thorough evaluations.

A look at LKQ Corporation Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, Lkq Corp has a positive long-term outlook. With high scores in value, dividend, and momentum, the company is positioned well for future growth and stability. Lkq Corp‘s focus on providing automotive products and services, along with its strong performance in terms of resilience and growth, further solidifies its position in the market.

Lkq Corp‘s impressive scores across various factors indicate a promising future for the company. With a strong emphasis on value and dividend, as well as a solid momentum score, Lkq Corp is poised for continued success in the automotive industry. Additionally, the company’s resilience and growth scores suggest that it is well-equipped to navigate challenges and capitalize on opportunities in the long run.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma

Centene Corporation (CNC)

59.49 USD +1.68 (+2.91%) Volume: 5.81M

Centene Corporation’s stock price stands at 59.49 USD, marking an impressive trading session increase of +2.91%. Despite a year-to-date decrease of -19.75%, the robust trading volume of 5.81M showcases the stock’s potential. Explore CNC’s dynamic performance and investment opportunities.

Latest developments on Centene Corporation

Recent insider buying activities at Centene Corp (CNC) have caught the attention of investors, with directors like Christopher Coughlin and Theodore Samuels purchasing significant amounts of company stock. Despite underperforming compared to competitors on Tuesday, the stock managed to outperform them on other days, showing resilience in the face of losses. With notable acquisitions by MML Investors Services LLC and Sanctuary Advisors LLC, it seems that confidence in Centene remains strong. Analysts at JPMorgan Chase & Co. have reaffirmed an overweight rating, while Jefferies expresses concerns with an underperform rating. Director Dallas H. James and Jessica Blume also joined in on the buying spree, indicating a positive outlook for Centene Corp‘s stock price movement.

Centene Corporation on Smartkarma

Analysts on Smartkarma, like Baptista Research, are optimistic about Centene Corp. According to Baptista Research‘s report, titled “Centene Corporation: Operational Efficiency & AI Utilization Driving Our Optimism! – Major Drivers,” the company’s third-quarter financial results for 2024 exceeded expectations. Centene Corporation achieved an adjusted diluted EPS of $1.62, attributing the outperformance to realized tax benefits and accelerated income tax benefits. The report highlights the company’s nuanced performance, showcasing strengths and ongoing challenges within its operations.

A look at Centene Corporation Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Centene Corporation, a multi-line managed care organization, is poised for a strong long-term outlook based on its Smartkarma Smart Scores. With top scores in Value and Growth, the company demonstrates solid fundamentals and potential for expansion. While its Dividend score is lower, Centene’s focus on providing Medicaid and Medicaid-related programs, along with specialty services like behavioral health, positions it well for future growth and success.

Although Centene Corp‘s Resilience and Momentum scores are moderate, its high scores in Value and Growth indicate a promising outlook. The company’s presence in multiple states and diverse range of health plans highlight its strong foundation in the healthcare industry. With a focus on innovation and providing essential healthcare services, Centene Corp is well-positioned to navigate challenges and capitalize on opportunities in the evolving healthcare landscape.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma

CVS Health Corporation (CVS)

45.28 USD +1.24 (+2.82%) Volume: 23.76M

CVS Health Corporation’s stock price sees a promising rise of +2.82% this trading session, reaching $45.28 with a robust trading volume of 23.76M, despite a challenging year-to-date percentage change of -42.65%.

Latest developments on CVS Health Corporation

CVS Health Corporation has been facing a tumultuous time in the stock market recently, with shares falling a further 17% in the past week alone. The healthcare giant has been hit from all sides, with challenges in its insurance business persisting and accusations of filling illegal opioid prescriptions. President Trump’s comments about ‘knocking out’ drug industry middlemen have also had a negative impact on CVS, UnitedHealth, and Cigna stock prices. The company’s stock is currently at its worst month in decades, with the Justice Department even suing CVS for alleged violations. Despite these challenges, CVS Health remains resilient, announcing pricing of maximum tender offers and debt tender offers amidst the stock price turmoil.

CVS Health Corporation on Smartkarma

Analysts at Baptista Research on Smartkarma have provided insightful coverage of Cvs Health Corp, highlighting key drivers of growth and strategic initiatives. In their report titled “CVS Health Corporation: Expansion & Optimization of Health Services As A Critical Factor Driving Growth! – Major Drivers,” they discuss the company’s third-quarter 2024 earnings report, noting a 6% increase in revenue to approximately $95.4 billion. However, challenges in the Health Care Benefits segment were indicated by the adjusted earnings per share of $1.09. The analysts’ bullish sentiment suggests optimism for CVS Health’s future prospects.

Furthermore, Baptista Research‘s analysis in the report “CVS Health Corporation: Strategic Leverage in Pharmacy Benefit Management (PBM) and Insurance Operations! – Major Drivers” delves into the company’s performance in the second quarter of 2024. They highlight mixed financial results, with adjusted earnings per share of $1.83 and revenues exceeding $91 billion. Operating cash flow of $8 billion for the first half of the year was supported by strong performances in the Health Services and Pharmacy & Consumer Wellness segments. This positive assessment underscores the potential strategic leverage CVS Health holds in its key operations.

A look at CVS Health Corporation Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, CVS Health Corp seems to have a positive long-term outlook. With high scores in both the value and dividend categories, the company appears to be a strong investment option for those looking for stability and potential returns. While the growth, resilience, and momentum scores are not as high, the overall outlook for CVS Health Corp remains promising.

As an integrated pharmacy health care provider, CVS Health Corporation offers a wide range of services including pharmacy benefit management, mail order, retail and specialty pharmacy, disease management programs, and retail clinics. With a strong presence in the U.S., the District of Columbia, and Puerto Rico, CVS Health Corp is well-positioned to continue providing essential healthcare services to communities across the country.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma

Cboe Global Markets, Inc. (CBOE)

200.07 USD +1.99 (+1.00%) Volume: 1.14M

Discover Cboe Global Markets, Inc.’s stock price performance, currently standing at 200.07 USD, marking a positive trading session with a 1.00% increase. With a robust trading volume of 1.14M, CBOE has shown a promising year-to-date percentage change of +12.05%, indicating a strong market presence and growth potential.

Latest developments on Cboe Global Markets, Inc.

Today, Cboe Global Markets Inc. stock is outperforming its competitors following a strong trading day. The company’s new vision is reflected in Cboe Data Vantage, showing proactive strategies in index options trading which continues to see growth as investors seek broader market exposure. Despite this positive momentum, EVP Adam Inzirillo recently sold $5,010 in stock. On Monday, Cboe Global Markets Inc. stock underperformed compared to competitors like Coinbase, which has ranked fifth globally in exchange revenue, surpassing Nasdaq and CBOE.

A look at Cboe Global Markets, Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Looking at the Smartkarma Smart Scores for Cboe Global Markets, the company’s long-term outlook appears to be positive. With a high score in Growth and Resilience, Cboe Global Markets shows potential for continued expansion and stability in the market. This indicates that the company is well-positioned to adapt to changing market conditions and sustain its growth over time.

While Cboe Global Markets may not score as high in Value and Dividend, its strong performance in Growth and Resilience suggests that investors may still find value in the company’s stock. With a solid momentum score as well, Cboe Global Markets seems to have the potential to maintain its upward trajectory in the future. Overall, the company’s Smart Scores paint a promising picture for its long-term prospects in the marketplace.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma

McKesson Corporation (MCK)

570.98 USD +8.20 (+1.46%) Volume: 1.13M

McKesson Corporation’s stock price soared to 570.98 USD, marking a positive shift of +1.46% in the latest trading session with a volume of 1.13M. This robust performance reflects an impressive YTD increase of +23.79%, highlighting MCK’s potent investment potential.

Latest developments on McKesson Corporation

McKesson Corp. stock experienced underperformance on Monday in comparison to its competitors. However, recent analyses from the Zacks Analyst Blog have highlighted McKesson alongside Doximity and Veracyte as promising investments. Additionally, financial experts like Gordon Reid have recommended adding McKesson stock to portfolios, citing its potential for growth. Recent moves in the market, such as B. Riley Wealth Advisors Inc. selling McKesson shares and Morgan Stanley raising the price target to $642.00, have also impacted the stock price movements today.

McKesson Corporation on Smartkarma

Analysts on Smartkarma, such as Baptista Research, have been closely covering Mckesson Corp and providing bullish insights on the company’s performance. In one report titled “McKesson Corporation: Will Its Cost Optimization & Operational Efficiencies Help Alter The Playing Field? – Major Drivers”, the analysts highlighted the company’s second quarter fiscal 2025 results, showing a robust 21% year-over-year revenue increase driven by the U.S. Pharmaceutical segment. Another report titled “McKesson Corporation: Expanding Oncology & Specialty Pharmaceutical Services As Well As Distribution & Sourcing! – Major Drivers” discussed the company’s first quarter fiscal 2025 earnings, which exceeded expectations with a 6% revenue increase and an adjusted earnings per share increase of 8%.

A look at McKesson Corporation Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

McKesson Corp, a company that distributes pharmaceuticals and medical supplies, has received high scores in Growth, Resilience, and Momentum according to Smartkarma Smart Scores. This indicates a positive long-term outlook for the company, suggesting strong potential for growth and the ability to weather economic challenges. With a focus on developing software and providing solutions for the healthcare industry, McKesson Corp is positioned well for continued success in the future.

While the company may not score as high in terms of value and dividend payouts, its strong performance in Growth, Resilience, and Momentum bodes well for investors looking for a company with long-term sustainability and potential for growth. McKesson Corp’s focus on data integration and healthcare solutions further solidifies its position as a key player in the industry, making it a company to watch for those interested in investing in the healthcare sector.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma